FY2024 EPS Estimates for TARS Increased by Lifesci Capital

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Analysts at Lifesci Capital raised their FY2024 earnings per share estimates for Tarsus Pharmaceuticals in a report released on Thursday, November 14th. Lifesci Capital analyst C. Jubinville now expects that the company will post earnings per share of ($3.05) for the year, up from their previous estimate of ($3.89). The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.41) per share. Lifesci Capital also issued estimates for Tarsus Pharmaceuticals’ Q4 2024 earnings at ($0.55) EPS.

TARS has been the topic of several other research reports. William Blair raised shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. The Goldman Sachs Group raised their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday. Finally, Oppenheimer upped their target price on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an “outperform” rating in a report on Thursday. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $54.20.

Tarsus Pharmaceuticals Price Performance

NASDAQ TARS opened at $44.83 on Monday. The business’s fifty day moving average is $37.84 and its 200 day moving average is $32.53. Tarsus Pharmaceuticals has a fifty-two week low of $15.60 and a fifty-two week high of $52.99. The company has a debt-to-equity ratio of 0.30, a quick ratio of 6.99 and a current ratio of 5.42. The company has a market capitalization of $1.71 billion, a PE ratio of -11.77 and a beta of 1.00.

Institutional Trading of Tarsus Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Swiss National Bank grew its stake in Tarsus Pharmaceuticals by 1.4% during the 1st quarter. Swiss National Bank now owns 42,433 shares of the company’s stock worth $1,542,000 after buying an additional 600 shares during the last quarter. Alpha DNA Investment Management LLC boosted its holdings in Tarsus Pharmaceuticals by 9.1% in the second quarter. Alpha DNA Investment Management LLC now owns 15,174 shares of the company’s stock worth $412,000 after acquiring an additional 1,261 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Tarsus Pharmaceuticals by 33.4% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock worth $166,000 after acquiring an additional 1,530 shares during the last quarter. Profund Advisors LLC grew its stake in shares of Tarsus Pharmaceuticals by 26.8% during the second quarter. Profund Advisors LLC now owns 9,126 shares of the company’s stock worth $248,000 after acquiring an additional 1,929 shares during the last quarter. Finally, Quest Partners LLC acquired a new position in shares of Tarsus Pharmaceuticals during the second quarter valued at about $61,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.